HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Price, Quote, News and Overview
EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR
HYL.BR Quote, Performance and Key Statistics
EBR:HYL (6/2/2025, 7:00:00 PM)
6.06
+0.16 (+2.71%)
The current stock price of HYL.BR is 6.06 EUR. In the past month the price increased by 4.66%. In the past year, price decreased by -50.93%.
HYL.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 54.47 | 622.10B | ||
| 1LLY.MI | ELI LILLY & CO | 53.88 | 615.27B | ||
| ZEG.DE | ASTRAZENECA PLC | 16.42 | 389.56B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.44 | 326.89B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.32 | 324.34B | ||
| NOV.DE | NOVO NORDISK A/S-B | 19.92 | 278.78B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.94 | 243.42B | ||
| SAN.PA | SANOFI | 11.2 | 209.53B | ||
| SNW.DE | SANOFI | 11.17 | 209.08B | ||
| NOT.DE | NOVARTIS AG-REG | 13.97 | 200.35B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 13.64 | 195.53B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.03 | 171.75B |
Related stock screener links
About HYL.BR
Company Profile
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege. The company went IPO on 2020-06-29. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
Company Info
HYLORIS PHARMACEUTICALS SA
Boulevard Patience et Beaujonc
Liege LIEGE BE
Employees: 24
Phone: 3243460207
HYLORIS PHARMACEUTICALS SA / HYL.BR FAQ
What is the stock price of HYLORIS PHARMACEUTICALS SA today?
The current stock price of HYL.BR is 6.06 EUR. The price increased by 2.71% in the last trading session.
What is the ticker symbol for HYLORIS PHARMACEUTICALS SA stock?
The exchange symbol of HYLORIS PHARMACEUTICALS SA is HYL and it is listed on the Euronext Brussels exchange.
On which exchange is HYL.BR stock listed?
HYL.BR stock is listed on the Euronext Brussels exchange.
What is the price forecast or stock price prediction for HYLORIS PHARMACEUTICALS SA stock?
7 analysts have analysed HYL.BR and the average price target is 13.94 EUR. This implies a price increase of 130.03% is expected in the next year compared to the current price of 6.06. Check the HYLORIS PHARMACEUTICALS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HYLORIS PHARMACEUTICALS SA worth?
HYLORIS PHARMACEUTICALS SA (HYL.BR) has a market capitalization of 169.68M EUR. This makes HYL.BR a Micro Cap stock.
How many employees does HYLORIS PHARMACEUTICALS SA have?
HYLORIS PHARMACEUTICALS SA (HYL.BR) currently has 24 employees.
What are the support and resistance levels for HYLORIS PHARMACEUTICALS SA (HYL.BR) stock?
HYLORIS PHARMACEUTICALS SA (HYL.BR) has a support level at 5.98 and a resistance level at 6.59. Check the full technical report for a detailed analysis of HYL.BR support and resistance levels.
Is HYLORIS PHARMACEUTICALS SA (HYL.BR) expected to grow?
The Revenue of HYLORIS PHARMACEUTICALS SA (HYL.BR) is expected to grow by 88.77% in the next year. Check the estimates tab for more information on the HYL.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HYLORIS PHARMACEUTICALS SA (HYL.BR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HYL.BR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HYL.BR, evaluating the profitability, health, valuation and growth aspects
- HYLORIS PHARMACEUTICALS SA (HYL.BR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HYLORIS PHARMACEUTICALS SA (HYL.BR) Sales and EPS estimates to see what analysts future expectations are.
- HYLORIS PHARMACEUTICALS SA (HYL.BR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HYLORIS PHARMACEUTICALS SA (HYL.BR) Insider and Institutional Ownership to learn about the owners and their transactions.
- HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Chart to make your own analysis
- HYLORIS PHARMACEUTICALS SA (HYL.BR) Latest news and press-releases to stay up to date.
Does HYLORIS PHARMACEUTICALS SA (HYL.BR) stock pay dividends?
HYL.BR does not pay a dividend.
What is the Price/Earnings (PE) ratio of HYLORIS PHARMACEUTICALS SA (HYL.BR)?
HYLORIS PHARMACEUTICALS SA (HYL.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
HYL.BR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HYL.BR. When comparing the yearly performance of all stocks, HYL.BR is a bad performer in the overall market: 89.78% of all stocks are doing better.
HYL.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR. The financial health of HYL.BR is average, but there are quite some concerns on its profitability.
HYL.BR Financial Highlights
Over the last trailing twelve months HYL.BR reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 55.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.34% | ||
| ROE | -19.73% | ||
| Debt/Equity | 0.06 |
HYL.BR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to HYL.BR. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 25.75% and a revenue growth 88.77% for HYL.BR